FDA Approves First Biosimilar Drug in U.S.

Share this content:
FDA Approves First Biosimilar Drug in U.S.
FDA Approves First Biosimilar Drug in U.S.

(HealthDay News) -- The U.S. Food and Drug Administration has approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.

Clinical studies showed Zarxio had no clinically meaningful difference in safety and effectiveness from Amgen Inc.'s Neupogen that was approved in 1991, the FDA said Friday in a news release. "Only minor differences in clinically inactive components are allowable in biosimilar products," the agency said in clarifying its definition of a biosimilar drug.

Zarxio is approved for the same indications as the already-sanctioned drug, including:

  • People with cancer who are on myelosuppressive chemotherapy.
  • People with acute myeloid leukemia who are on induction or consolidation chemotherapy.
  • People with cancer who are having bone marrow transplant.
  • People who are having autologous peripheral blood progenitor cell collection/therapy.
  • People with severe chronic neutropenia.

The most common clinical side effects of Zarxio include pain in the bones and muscles, and redness, swelling and itching at the injection site. More serious adverse reactions could include spleen rupture, serious allergic reaction and acute respiratory distress syndrome, the FDA said.

Biosimilar drugs are permitted under the Biologics Price Competition and Innovation Act of 2009, part of the Affordable Care Act signed by President Barack Obama in 2010, the FDA said. Zarxio is produced by Novartis, based in Princeton, N.J.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Cognitive Disability Most Prevalent Type in Young Adults

Cognitive Disability Most Prevalent Type in Young Adults

Disability-specific disparities prevalent in access to health care, especially for young, middle-aged adults

Declines in Life Expectancy in Many High-Income Countries

Declines in Life Expectancy in Many High-Income Countries

And increase in midlife death rates across racial and ethnic groups in the United States

Tobacco Content Still Common on U.K. Prime-Time Television

Tobacco Content Still Common on U.K. Prime-Time Television

Tobacco content occurred in 33 percent of all programs; 8 percent of all adverts, trailer breaks

is free, fast, and customized just for you!




Already a member?

Sign In Now »